JP2013526863A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013526863A5 JP2013526863A5 JP2013509571A JP2013509571A JP2013526863A5 JP 2013526863 A5 JP2013526863 A5 JP 2013526863A5 JP 2013509571 A JP2013509571 A JP 2013509571A JP 2013509571 A JP2013509571 A JP 2013509571A JP 2013526863 A5 JP2013526863 A5 JP 2013526863A5
- Authority
- JP
- Japan
- Prior art keywords
- genes
- cell carcinoma
- renal cell
- discontinuous
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 claims 31
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 29
- 238000000034 method Methods 0.000 claims 9
- 241001465754 Metazoa Species 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 230000004043 responsiveness Effects 0.000 claims 2
- 238000013517 stratification Methods 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33431810P | 2010-05-13 | 2010-05-13 | |
| EP10162783.4 | 2010-05-13 | ||
| US61/334,318 | 2010-05-13 | ||
| EP10162783 | 2010-05-13 | ||
| PCT/EP2011/057691 WO2011141544A1 (en) | 2010-05-13 | 2011-05-12 | Discrete states for use as biomarkers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013526863A JP2013526863A (ja) | 2013-06-27 |
| JP2013526863A5 true JP2013526863A5 (enExample) | 2014-06-19 |
Family
ID=43127799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013509571A Withdrawn JP2013526863A (ja) | 2010-05-13 | 2011-05-12 | バイオマーカーとして用いるための不連続状態 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130157887A1 (enExample) |
| EP (1) | EP2569636A1 (enExample) |
| JP (1) | JP2013526863A (enExample) |
| CA (1) | CA2798434A1 (enExample) |
| WO (1) | WO2011141544A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7838250B1 (en) | 2006-04-04 | 2010-11-23 | Singulex, Inc. | Highly sensitive system and methods for analysis of troponin |
| CN101432626B (zh) | 2006-04-04 | 2013-06-19 | 神谷来克斯公司 | 用于肌钙蛋白分析的高灵敏系统和方法 |
| AU2010259022B2 (en) | 2009-06-08 | 2016-05-12 | Singulex, Inc. | Highly sensitive biomarker panels |
| EP3722444B1 (en) * | 2019-04-12 | 2024-06-05 | Robert Bosch Gesellschaft für medizinische Forschung mbH | Method for determining rcc subtypes |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2611728A1 (en) * | 2005-06-08 | 2006-12-14 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with cancer therapy |
| WO2008128043A2 (en) * | 2007-04-11 | 2008-10-23 | The General Hospital Corporation | Diagnostic and prognostic methods for renal cell carcinoma |
-
2011
- 2011-05-12 US US13/697,419 patent/US20130157887A1/en not_active Abandoned
- 2011-05-12 WO PCT/EP2011/057691 patent/WO2011141544A1/en not_active Ceased
- 2011-05-12 CA CA2798434A patent/CA2798434A1/en not_active Abandoned
- 2011-05-12 EP EP11719551A patent/EP2569636A1/en not_active Withdrawn
- 2011-05-12 JP JP2013509571A patent/JP2013526863A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Remon et al. | Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA | |
| Hu et al. | The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies | |
| US20220056541A1 (en) | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer | |
| CA3109391A1 (en) | Methods related to bronchial premalignant lesion severity and progression | |
| JP2014144959A5 (enExample) | ||
| Ye et al. | The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma | |
| CA2812940A1 (en) | Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease | |
| BR112015023783A2 (pt) | método para diagnóstico e tratamento de metastase no câncer | |
| CN105636594A (zh) | 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物 | |
| Díaz-González et al. | Surveillance for hepatocellular carcinoma | |
| JP2011177182A5 (enExample) | ||
| JP2009540314A5 (enExample) | ||
| JP2017505897A5 (enExample) | ||
| CN106148529A (zh) | 与胃癌相关的LncRNA标记物及其专用检测引物、检测方法、试剂盒与应用 | |
| JP2013526863A5 (enExample) | ||
| Li et al. | Increased serum FGF2 levels in first-episode, drug-free patients with schizophrenia | |
| Rasmussen et al. | Early transcriptional programming links progression to hepatitis C virus–induced severe liver disease in transplant patients | |
| JP2012520446A5 (enExample) | ||
| Gregori et al. | Abnormal regulation of renin angiotensin aldosterone system is associated with right ventricular dysfunction in hypertension | |
| Strak et al. | A study of lichen planus and its association with hepatitis C infection | |
| Dweep et al. | Mechanistic roles of microRNAs in hepatocarcinogenesis: A study of thioacetamide with multiple doses and time-points of rats | |
| WO2011073905A8 (en) | Novel tumor markers | |
| Murray et al. | Stress and withdrawal from d-amphetamine alter 5-HT2A receptor mRNA expression in the prefrontal cortex | |
| CN104164500B (zh) | miRNA标志物hsa-miR-486-5p的应用 | |
| Sherman | Whither hepatocellular carcinoma screening? |